Types of Reproductive and Fertility Disorders: Which Are Being Studied With Stem Cell Therapy?

Reproductive and fertility medicine is one of the most active corners of regenerative research today — but "active research" and "proven treatment" are very different things. This overview maps the reproductive conditions where stem cell or cell-based approaches actually have credible science behind them, distinguishes those from conditions where the connection is speculative or purely mechanistic, and situates several topics we cover in standalone deep dives (female and male infertility, premature ovarian insufficiency, Asherman's syndrome, and endometriosis) alongside newer areas of interest: thin endometrium and recurrent implantation failure, polycystic ovary syndrome (PCOS), azoospermia, fertility preservation after chemotherapy, and uterine fibroids.

Why Reproductive Conditions Are a Different Research Category

Unlike a damaged joint or a scarred heart, reproductive tissue is built to regenerate on a monthly cycle, which makes it an unusually attractive — and unusually complicated — target for cell therapy. The endometrium rebuilds itself every month, ovarian and testicular tissue depend on small, hard-to-isolate stem cell populations, and almost every condition in this category ultimately gets judged by one outcome: a live birth, not just a lab marker. That high bar, combined with the ethical complexity of studying fertility interventions, means most work here is still in early human trials or animal models rather than large, randomized studies — important context for every subtype below.

Where the Evidence Is Genuinely Encouraging

Thin endometrium and recurrent implantation failure (RIF). This is arguably the most promising corner of reproductive cell therapy right now. Small studies using autologous bone marrow-derived or endometrial mesenchymal stem cells (MSCs) to treat women with endometrial linings too thin to sustain pregnancy have reported meaningful increases in endometrial thickness and, in some cases, subsequent pregnancies — leading a 2020 case series in JBRA Assisted Reproduction to call it a "novel strategy" worth pursuing further. A US academic medical center has run a clinical trial mobilizing bone marrow-derived stem cells specifically for thin endometrium, Asherman's-related scarring, and RIF together, reflecting how closely these conditions are mechanistically linked — all trace back to a damaged or under-responsive endometrial lining. A 2025 Frontiers in Cell and Developmental Biology review of regenerative approaches for refractory thin endometrium reinforces that this is one of the more active, well-reasoned niches in the field.

Fertility preservation and ovarian tissue. For patients facing chemotherapy or radiation, ovarian tissue cryopreservation — removing and freezing ovarian tissue before treatment for later reimplantation — is already a real, used clinical option, and stem cell biology is now being explored to make it better. Researchers are studying how stem and progenitor cells within cryopreserved ovarian tissue survive transplantation and whether supportive cell populations can improve graft survival and hormone recovery after reimplantation. This is a genuinely hopeful area precisely because it builds on a technique with an established track record, rather than starting from zero.

Male factor infertility: azoospermia. For men with non-obstructive azoospermia (no sperm due to failed sperm production, as opposed to a blockage), researchers have explored both mesenchymal stem cell injections and spermatogonial stem cell (SSC) transplantation aimed at restarting sperm production. A registered trial (ClinicalTrials.gov NCT02025270) tested bone marrow-derived MSCs in azoospermic men, and SSC transplant and testicular tissue grafting approaches remain active areas of trial design. Results so far are early and mixed, but the biological rationale — replacing or supporting the stem cells that normally generate sperm — is sound enough to keep this research moving.

Polycystic ovary syndrome (PCOS). Animal studies have shown that mesenchymal stem cells and their secreted extracellular vesicles can reduce the ovarian inflammation and hormonal disruption seen in PCOS models, improving markers of ovarian function. It's encouraging mechanistic work, but it remains preclinical — these are mouse studies, not treatments offered to PCOS patients trying to conceive.

Where the Science Is Not There Yet

Uterine fibroids deserve a specific caution. Fibroids themselves are now understood to arise from a single mutated stem-cell-like progenitor cell within the uterine muscle wall — meaning stem cell biology is central to explaining what fibroids are, not to treating them. There is currently no credible stem-cell therapy for shrinking or eliminating fibroids; research in this space is aimed at understanding fibroid origin and growth, a meaningfully different thing from a regenerative treatment. Erectile dysfunction has far more developed (though still investigational) cell-therapy research, which we cover separately. And no condition in this entire category has an FDA-approved stem cell product — a point underscored by the FDA's continued enforcement actions against reproductive and fertility clinics marketing unapproved stem cell offerings, including a warning letter issued in 2025.

Bottom Line

Reproductive and fertility medicine has some real, encouraging pockets of stem cell research — thin endometrium and implantation failure, fertility preservation, and male factor infertility among them — built on small human trials and registered studies rather than wishful thinking. Other areas, like PCOS, are promising in animal models but far from clinical reality, and fibroids illustrate how stem cell biology can explain a disease without yet offering a stem-cell treatment for it. No therapy here is FDA-approved, and anyone considering an investigational option should treat clinic marketing claims with the same scrutiny this article applies to the research itself.